The emerging role of nutrition in Parkinson's disease

Frontiers in Aging Neuroscience

Volumn 6, Issue MAR, 2014, Pages

  Seidl, Stacey E ^a   Santiago, Jose A ^a   Bilyk, Hope ^a   Potashkin, Judith A ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Antioxidants; Neurodegeneration; Neuroprotection; Nutrition; Parkinson's disease

Indexed keywords

ALCOHOL; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CAFFEINE; CARBOHYDRATE; FAT; GENISTEIN; OMEGA 3 FATTY ACID; VITAMIN D;

ALCOHOL CONSUMPTION; DISEASE COURSE; EPIGENETICS; FAT INTAKE; HUMAN; MEAT; NERVE DEGENERATION; NEUROPROTECTION; NUTRITIONAL STATUS; PARKINSON DISEASE; REVIEW; RISK FACTOR; TEA; VITAMIN SUPPLEMENTATION;

EID: 84898042544     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00036     Document Type: Review

References (249)

1. Abbott, R. D., Ross, G. W., White, L. R., Sanderson, W. T., Burchfiel, C. M., Kashon, M., et al. (2003). Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J. Neurol. 250(Suppl. 3), III30-III39. doi: 10.1007/s00415-003-1306-7
2. Aguiar, L. M., Nobre, H. V. Jr., Macedo, D. S., Oliveira, A. A., Freitas, R. M., Vasconcelos, S. M., et al. (2006). Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol. Biochem. Behav. 84, 415-419. doi: 10.1016/j.pbb.2006.05.027
3. Akbar, M., and Kim, H. Y. (2002). Protective effects of docosahexaenoic acid in staurosporine-induced apoptosis: involvement of phosphatidylinositol-3 kinase pathway. J. Neurochem. 82, 655-665. doi: 10.1046/j.1471-4159.2002.01015.x
4. Alcalay, R. N., Gu, Y., Mejia-Santana, H., Cote, L., Marder, K. S., and Scarmeas, N. (2012). The association between Mediterranean diet adherence and Parkinson's disease. Mov. Disord. 27, 771-774. doi: 10.1002/mds.24918
5. Altman, R. D., Lang, A. E., and Postuma, R. B. (2011). Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov. Disord. 26, 2427-2431. doi: 10.1002/mds.23873
6. Alvira, D., Yeste-Velasco, M., Folch, J., Verdaguer, E., Canudas, A. M., Pallas, M., et al. (2007). Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience 147, 746-756. doi: 10.1016/j.neuroscience.2007.04.029
7. Ambani, L. M., Van Woert, M. H., and Murphy, S. (1975). Brain peroxidase and catalase in Parkinson disease. Arch. Neurol. 32, 114-118. doi: 10.1001/archneur.1975.00490440064010
8. Anandhan, A., Tamilselvam, K., Radhiga, T., Rao, S., Essa, M. M., and Manivasagam, T. (2012). Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease. Brain Res. 1433, 104-113. doi: 10.1016/j.brainres.2011.11.021
9. Anderson, C., Checkoway, H., Franklin, G. M., Beresford, S., Smith-Weller, T., and Swanson, P. D. (1999). Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov. Disord. 14, 21-27. doi: 10.1002/1531-8257(199901)14:1<21::AID-MDS1006>3.0.CO;2-Y
10. Andreadou, E., Nikolaou, C., Gournaras, F., Rentzos, M., Boufidou, F., Tsoutsou, A., et al. (2009). Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin. Neurol. Neurosurg. 111, 724-728. doi: 10.1016/j.clineuro.2009.06.012
11. Aneja, R., Odoms, K., Denenberg, A. G., and Wong, H. R. (2004). Theaflavin, a black tea extract, is a novel anti-inflammatory compound. Crit. Care Med. 32, 2097-2103. doi: 10.1097/01.CCM.0000142661.73633.15
12. Ascherio, A., Chen, H., Schwarzschild, M. A., Zhang, S. M., Colditz, G. A., and Speizer, F. E. (2003). Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 60, 790-795. doi: 10.1212/01.WNL.0000046523.05125.87
13. Ascherio, A., Zhang, S. M., Hernan, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., et al. (2001). Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 50, 56-63. doi: 10.1002/ana.1052
14. Babenko, O., Kovalchuk, I., and Metz, G. A. (2012). Epigenetic programming of neurodegenerative diseases by an adverse environment. Brain Res. 1444, 96-111. doi: 10.1016/j.brainres.2012.01.038
15. Baluchnejadmojarad, T., Roghani, M., Nadoushan, M. R., and Bagheri, M. (2009). Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model. Phytother. Res. 23, 132-135. doi: 10.1002/ptr.2564
16. Barichella, M., Cereda, E., and Pezzoli, G. (2009). Major nutritional issues in the management of Parkinson's disease. Mov. Disord. 24, 1881-1892. doi: 10.1002/mds.22705
17. Barkhoudarian, M. T., and Schwarzschild, M. A. (2011). Preclinical jockeying on the translational track of adenosine A2A receptors. Exp. Neurol. 228, 160-164. doi: 10.1016/j.expneurol.2010.12.022
18. Bastianetto, S., Yao, Z. X., Papadopoulos, V., and Quirion, R. (2006). Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Eur. J. Neurosci. 23, 55-64. doi: 10.1111/j.1460-9568.2005.04532.x
19. Bazan, N. G. (2009). Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J. Lipid Res. 50(Suppl.), S400-S405. doi: 10.1194/jlr. R800068-JLR200
20. Beal, M. F. (2003). Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci. 991, 120-131. doi: 10.1111/j.1749-6632.2003.tb07470.x
21. Benedetti, M. D., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., et al. (2000). Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 55, 1350-1358. doi: 10.1212/WNL.55.9.1350
22. Berry, E. M., Growdon, J. H., Wurtman, J. J., Caballero, B., and Wurtman, R. J. (1991). A balanced carbohydrate: protein diet in the management of Parkinson's disease. Neurology 41, 1295-1297. doi: 10.1212/WNL.41.8.1295
23. Blanchet, J., Longpre, F., Bureau, G., Morissette, M., Dipaolo, T., Bronchti, G., et al. (2008). Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1243-1250. doi: 10.1016/j.pnpbp.2008.03.024
24. Blok, W. L., Katan, M. B., and Van Der Meer, J. W. (1996). Modulation of inflammation and cytokine production by dietary (n-3) fatty acids. J. Nutr. 126, 1515-1533.
25. Bournival, J., Plouffe, M., Renaud, J., Provencher, C., and Martinoli, M. G. (2012). Quercetin and sesamin protect dopaminergic cells from MPP+-induced neuroinflammation in a microglial (N9)-neuronal (PC12) coculture system. Oxid. Med. Cell. Longev. 2012, 921941. doi: 10.1155/2012/921941
26. Bournival, J., Quessy, P., and Martinoli, M. G. (2009). Protective effects of resveratrol and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell. Mol. Neurobiol. 29, 1169-1180. doi: 10.1007/s10571-009-9411-5
27. Bousquet, M., Calon, F., and Cicchetti, F. (2011a). Impact of omega-3 fatty acids in Parkinson's disease. Ageing Res. Rev. 10, 453-463. doi: 10.1016/j.arr.2011.03.001
28. Bousquet, M., Saint-Pierre, M., Julien, C., Salem, N. Jr., Cicchetti, F., and Calon, F. (2008). Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J. 22, 1213-1225. doi: 10.1096/fj.07-9677com
29. Bousquet, M., St-Amour, I., Vandal, M., Julien, P., Cicchetti, F., and Calon, F. (2011b). High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice. Neurobiol. Dis. 45, 529-538. doi: 10.1016/j.nbd.2011.09.009
30. Bureau, G., Longpre, F., and Martinoli, M. G. (2008). Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J. Neurosci. Res. 86, 403-410. doi: 10.1002/jnr.21503
31. Calon, F., Lim, G. P., Morihara, T., Yang, F., Ubeda, O., Salem, N., et al. (2005). Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur. J. Neurosci. 22, 617-626. doi: 10.1111/j.1460-9568.2005.04253.x
32. Calon, F., Lim, G. P., Yang, F., Morihara, T., Teter, B., Ubeda, O., et al. (2004). Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43, 633-645. doi: 10.1016/j.neuron.2004.08.013
33. Cansev, M., Ulus, I. H., Wang, L., Maher, T. J., and Wurtman, R. J. (2008). Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease. Neurosci. Res. 62, 206-209. doi: 10.1016/j.neures.2008.07.005
34. Cassani, E., Cereda, E., Barichella, M., Madio, C., Cancello, R., Caccialanza, R., et al. (2013). Cardiometabolic factors and disease duration in patients with Parkinson's disease. Nutrition 29, 1331-1335. doi: 10.1016/j.nut.2013.04.013
35. Cereda, E., Barichella, M., Pedrolli, C., Klersy, C., Cassani, E., Caccialanza, R., et al. (2013). Diabetes and risk of Parkinson's disease. Mov. Disord. 28, 257. doi: 10.1002/mds.25211
36. Chan, C. S., Gertler, T. S., and Surmeier, D. J. (2009). Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci. 32, 249-256. doi: 10.1016/j.tins.2009.01.006
37. Chan, D. K., Woo, J., Ho, S. C., Pang, C. P., Law, L. K., Ng, P. W., et al. (1998). Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J. Neurol. Neurosurg. Psychiatry 65, 781-784. doi: 10.1136/jnnp.65.5.781
38. Chaturvedi, R. K., Shukla, S., Seth, K., Chauhan, S., Sinha, C., Shukla, Y., et al. (2006). Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neurobiol. Dis. 22, 421-434. doi: 10.1016/j.nbd.2005.12.008
39. Checkoway, H., Powers, K., Smith-Weller, T., Franklin, G. M., Longstreth, W. T. Jr., and Swanson, P. D. (2002). Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am. J. Epidemiol. 155, 732-738. doi: 10.1093/aje/155.8.732
40. Chen, H., O'Reilly, E., McCullough, M. L., Rodriguez, C., Schwarzschild, M. A., Calle, E. E., et al. (2007a). Consumption of dairy products and risk of Parkinson's disease. Am. J. Epidemiol. 165, 998-1006. doi: 10.1093/aje/kwk089
41. Chen, H., Zhang, S. M., Hernan, M. A., Willett, W. C., and Ascherio, A. (2002). Diet and Parkinson's disease: a potential role of dairy products in men. Ann. Neurol. 52, 793-801. doi: 10.1002/ana.10381
42. Chen, H., Zhang, S. M., Hernan, M. A., Willett, W. C., and Ascherio, A. (2003). Dietary intakes of fat and risk of Parkinson's disease. Am. J. Epidemiol. 157, 1007-1014. doi: 10.1093/aje/kwg073
43. Chen, H., Zhang, S. M., Schwarzschild, M. A., Hernan, M. A., Logroscino, G., Willett, W. C., et al. (2004). Folate intake and risk of Parkinson's disease. Am. J. Epidemiol. 160, 368-375. doi: 10.1093/aje/kwh213
44. Chen, J. F., Sonsalla, P. K., Pedata, F., Melani, A., Domenici, M. R., Popoli, P., et al. (2007b). Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog. Neurobiol. 83, 310-331. doi: 10.1016/j.pneurobio.2007.09.002
45. Chen, J. F., Xu, K., Petzer, J. P., Staal, R., Xu, Y. H., Beilstein, M., et al. (2001). Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21, RC143.
46. Chi, D. S., Gong, L., Daigneault, E. A., and Kostrzewa, R. M. (1992). Effects of MPTP and vitamin E treatments on immune function in mice. Int. J. Immunopharmacol. 14, 739-746. doi: 10.1016/0192-0561(92)90070-2
47. Choi, H. K., Liu, S., and Curhan, G. (2005a). Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 52, 283-289. doi: 10.1002/art.20761
48. Choi, J. Y., Jang, E. H., Park, C. S., and Kang, J. H. (2005b). Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. Free Radic. Biol. Med. 38, 806-816. doi: 10.1016/j.freeradbiomed.2004.12.008
49. Choi, J. Y., Park, C. S., Kim, D. J., Cho, M. H., Jin, B. K., Pie, J. E., et al. (2002). Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology 23, 367-374. doi: 10.1016/S0161-813X(02)00079-7
50. Cleren, C., Yang, L., Lorenzo, B., Calingasan, N. Y., Schomer, A., Sireci, A., et al. (2008). Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J. Neurochem. 104, 1613-1621. doi: 10.1111/j.1471-4159.2007.05097.x
51. Coimbra, C. G., and Junqueira, V. B. (2003). High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients. Braz. J. Med. Biol. Res. 36, 1409-1417. doi: 10.1590/S0100-879X2003001000019
52. Colette, C., Percheron, C., Pares-Herbute, N., Michel, F., Pham, T. C., Brillant, L., et al. (2003). Exchanging carbohydrates for monounsaturated fats in energy-restricted diets: effects on metabolic profile and other cardiovascular risk factors. Int. J. Obes. Relat. Metab. Disord. 27, 648-656. doi: 10.1038/sj.ijo.0802299
53. Corrigan, F. M., Murray, L., Wyatt, C. L., and Shore, R. F. (1998). Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease. Exp. Neurol. 150, 339-342. doi: 10.1006/exnr.1998.6776
54. Costa, J., Lunet, N., Santos, C., Santos, J., and Vaz-Carneiro, A. (2010). Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. J. Alzheimers Dis. 20(Suppl. 1), S221-S238. doi: 10.3233/JAD-2010-091525
55. Crevoisier, C., Zerr, P., Calvi-Gries, F., and Nilsen, T. (2003). Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. Eur. J. Pharm. Biopharm. 55, 71-76. doi: 10.1016/S0939-6411(02)00124-8
56. Da Silva, T. M., Munhoz, R. P., Alvarez, C., Naliwaiko, K., Kiss, A., Andreatini, R., et al. (2008). Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J. Affect. Disord. 111, 351-359. doi: 10.1016/j.jad.2008.03.008
57. Dauncey, M. J. (1997). From early nutrition and later development.. to underlying mechanisms and optimal health. Br. J. Nutr. 78(Suppl. 2), S113-S123. doi: 10.1079/BJN19970226
58. Dauncey, M. J. (2012). Recent advances in nutrition, genes and brain health. Proc. Nutr. Soc. 71, 581-591. doi: 10.1017/S0029665112000237
59. Dauncey, M. J. (2013). Genomic and epigenomic insights into nutrition and brain disorders. Nutrients 5, 887-914. doi: 10.3390/nu5030887
60. Dauncey, M. J., and Bicknell, R. J. (1999). Nutrition and neurodevelopment: mechanisms of developmental dysfunction and disease in later life. Nutr. Res. Rev. 12, 231-253. doi: 10.1079/095442299108728947
61. Dauncey, M. J., White, P., Burton, K. A., and Katsumata, M. (2001). Nutrition-hormone receptor-gene interactions: implications for development and disease. Proc. Nutr. Soc. 60, 63-72. doi: 10.1079/PNS200071
62. De Lau, L. M., Bornebroek, M., Witteman, J. C., Hofman, A., Koudstaal, P. J., and Breteler, M. M. (2005). Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology 64, 2040-2045. doi: 10.1212/01.WNL.0000166038.67153.9F
63. De Lau, L. M., Koudstaal, P. J., Hofman, A., and Breteler, M. M. (2006). Serum cholesterol levels and the risk of Parkinson's disease. Am. J. Epidemiol. 164, 998-1002. doi: 10.1093/aje/kwj283
64. De Urquiza, A. M., Liu, S., Sjoberg, M., Zetterstrom, R. H., Griffiths, W., Sjovall, J., et al. (2000). Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290, 2140-2144. doi: 10.1126/science.290.5499.2140
65. Du, G., Lewis, M. M., Shaffer, M. L., Chen, H., Yang, Q. X., Mailman, R. B., et al. (2012). Serum cholesterol and nigrostriatal R2* values in Parkinson's disease. PLoS ONE 7:e35397. doi: 10.1371/journal.pone.0035397
66. Etminan, M., Gill, S. S., and Samii, A. (2005). Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol. 4, 362-365. doi: 10.1016/S1474-4422(05)70097-1
67. Fahn, S. (1992). A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann. Neurol. 32(Suppl.), S128-S132. doi: 10.1002/ana.410320722
68. Fall, P. A., Fredrikson, M., Axelson, O., and Granerus, A. K. (1999). Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov. Disord. 14, 28-37. doi: 10.1002/1531-8257(199901)14:1<28::AID-MDS1007>3.0.CO;2-O
69. Farooqui, A. A., and Horrocks, L. A. (1998). Lipid peroxides in the free radical pathophysiology of brain diseases. Cell. Mol. Neurobiol. 18, 599-608. doi: 10.1023/A:1020261600498
70. Fernandez-Calle, P., Molina, J. A., Jimenez-Jimenez, F. J., Vazquez, A., Pondal, M., Garcia-Ruiz, P. J., et al. (1992). Serum levels of alpha-tocopherol (vitamin E) in Parkinson's disease. Neurology 42, 1064-1066. doi: 10.1212/WNL.42.5.1064
71. Fernstrom, J. D. (1999). Effects of dietary polyunsaturated fatty acids on neuronal function. Lipids 34, 161-169. doi: 10.1007/s11745-999-0350-3
72. Fernstrom, J. D., Wurtman, R. J., Hammarstrom-Wiklund, B., Rand, W. M., Munro, H. N., and Davidson, C. S. (1979). Diurnal variations in plasma concentrations of tryptophan, tryosine, and other neutral amino acids: effect of dietary protein intake. Am. J. Clin. Nutr. 32, 1912-1922.
73. Ferraz, H. B., Quagliato, E. A., Rieder, C. R., Silva, D. J., Teive, H. A., Barbosa, E. R., et al. (2004). Comments on the paper "High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients. C.G. Coimbra and V.B.C. Junqueira. Brazilian Journal of Medical and Biological Research, 36: 1409-1417, 2003". Braz. J. Med. Biol. Res. 37, 1297-1299. discussion: 1299-1302. doi: 10.1590/S0100-879X2004000900002
74. Fleming, L., Mann, J. B., Bean, J., Briggle, T., and Sanchez-Ramos, J. R. (1994). Parkinson's disease and brain levels of organochlorine pesticides. Ann. Neurol. 36, 100-103. doi: 10.1002/ana.410360119
75. Gaenslen, A., Gasser, T., and Berg, D. (2008). Nutrition and the risk for Parkinson's disease: review of the literature. J. Neural Transm. 115, 703-713. doi: 10.1007/s00702-007-0005-4
76. Gao, X., Chen, H., Choi, H. K., Curhan, G., Schwarzschild, M. A., and Ascherio, A. (2008). Diet, urate, and Parkinson's disease risk in men. Am. J. Epidemiol. 167, 831-838. doi: 10.1093/aje/kwm385
77. Gao, X., Chen, H., Fung, T. T., Logroscino, G., Schwarzschild, M. A., Hu, F. B., et al. (2007). Prospective study of dietary pattern and risk of Parkinson disease. Am. J. Clin. Nutr. 86, 1486-1494.
78. Garcion, E., Wion-Barbot, N., Montero-Menei, C. N., Berger, F., and Wion, D. (2002). New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab. 13, 100-105. doi: 10.1016/S1043-2760(01)00547-1
79. Gasior, M., Rogawski, M. A., and Hartman, A. L. (2006). Neuroprotective and disease-modifying effects of the ketogenic diet. Behav. Pharmacol. 17, 431-439. doi: 10.1097/00008877-200609000-00009
80. Gleichmann, M., and Mattson, M. P. (2011). Neuronal calcium homeostasis and dysregulation. Antioxid. Redox Signal. 14, 1261-1273. doi: 10.1089/ars.2010.3386
81. Golembiowska, K., and Dziubina, A. (2012). The effect of adenosine A(2A) receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2. Neurotox. Res. 22, 150-157. doi: 10.1007/s12640-012-9316-9
82. Gong, L., Daigneault, E. A., Acuff, R. V., and Kostrzewa, R. M. (1991). Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity. Neuroreport 2, 544-546. doi: 10.1097/00001756-199109000-00012
83. Gosslau, A., En Jao, D. L., Huang, M. T., Ho, C. T., Evans, D., Rawson, N. E., et al. (2011). Effects of the black tea polyphenol theaflavin-2 on apoptotic and inflammatory pathways in vitro and in vivo. Mol. Nutr. Food Res. 55, 198-208. doi: 10.1002/mnfr.201000165
84. Green, K. N., Martinez-Coria, H., Khashwji, H., Hall, E. B., Yurko-Mauro, K. A., Ellis, L., et al. (2007). Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J. Neurosci. 27, 4385-4395. doi: 10.1523/JNEUROSCI.0055-07.2007
85. Guo, S., Yan, J., Yang, T., Yang, X., Bezard, E., and Zhao, B. (2007). Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway. Biol. Psychiatry 62, 1353-1362. doi: 10.1016/j.biopsych.2007.04.020
86. Hackett, J. A., Zylicz, J. J., and Surani, M. A. (2012). Parallel mechanisms of epigenetic reprogramming in the germline. Trends Genet. 28, 164-174. doi: 10.1016/j.tig.2012.01.005
87. Hartman, R. E., Shah, A., Fagan, A. M., Schwetye, K. E., Parsadanian, M., Schulman, R. N., et al. (2006). Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiol. Dis. 24, 506-515. doi: 10.1016/j.nbd.2006.08.006
88. Hashimoto, M., Tanabe, Y., Fujii, Y., Kikuta, T., Shibata, H., and Shido, O. (2005). Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J. Nutr. 135, 549-555.
89. Hassan, A., Ibrahim, A., Mbodji, K., Coeffier, M., Ziegler, F., Bounoure, F., et al. (2010). An alpha-linolenic acid-rich formula reduces oxidative stress and inflammation by regulating NF-kappaB in rats with TNBS-induced colitis. J. Nutr. 140, 1714-1721. doi: 10.3945/jn.109.119768
90. Hellenbrand, W., Boeing, H., Robra, B. P., Seidler, A., Vieregge, P., Nischan, P., et al. (1996a). Diet and Parkinson's disease. II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 47, 644-650. doi: 10.1212/WNL.47.3.644
91. Hellenbrand, W., Seidler, A., Boeing, H., Robra, B. P., Vieregge, P., Nischan, P., et al. (1996b). Diet and Parkinson's disease. I: a possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 47, 636-643. doi: 10.1212/WNL.47.3.636
92. Hellenbrand, W., Seidler, A., Robra, B. P., Vieregge, P., Oertel, W. H., Joerg, J., et al. (1997). Smoking and Parkinson's disease: a case-control study in Germany. Int. J. Epidemiol. 26, 328-339. doi: 10.1093/ije/26.2.328
93. Hernan, M. A., Chen, H., Schwarzschild, M. A., and Ascherio, A. (2003). Alcohol consumption and the incidence of Parkinson's disease. Ann. Neurol. 54, 170-175. doi: 10.1002/ana.10611
94. Hickey, P., and Stacy, M. (2011). Available and emerging treatments for Parkinson's disease: a review. Drug Des. Devel. Ther. 5, 241-254. doi: 10.2147/DDDT.S11836
95. Holick, M. F. (2007). Vitamin D deficiency. N. Engl. J. Med. 357, 266-281. doi: 10.1056/NEJMra070553
96. Horrocks, L. A., and Yeo, Y. K. (1999). Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res. 40, 211-225. doi: 10.1006/phrs.1999.0495
97. Hu, G. (2010). Total cholesterol and the risk of Parkinson's disease: a review for some new findings. Parkinsons Dis. 2010, 836962. doi: 10.4061/2010/836962
98. Hu, G., Bidel, S., Jousilahti, P., Antikainen, R., and Tuomilehto, J. (2007). Coffee and tea consumption and the risk of Parkinson's disease. Mov. Disord. 22, 2242-2248. doi: 10.1002/mds.21706
99. Huang, X., Auinger, P., Eberly, S., Oakes, D., Schwarzschild, M., Ascherio, A., et al. (2011). Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. PLoS ONE 6:e22854. doi: 10.1371/journal.pone.0022854
100. Jin, F., Wu, Q., Lu, Y. F., Gong, Q. H., and Shi, J. S. (2008). Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur. J. Pharmacol. 600, 78-82. doi: 10.1016/j.ejphar.2008.10.005
101. Joghataie, M. T., Roghani, M., Negahdar, F., and Hashemi, L. (2004). Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. Parkinsonism Relat. Disord. 10, 465-468. doi: 10.1016/j.parkreldis.2004.06.004
102. Johnson, C. C., Gorell, J. M., Rybicki, B. A., Sanders, K., and Peterson, E. L. (1999). Adult nutrient intake as a risk factor for Parkinson's disease. Int. J. Epidemiol. 28, 1102-1109. doi: 10.1093/ije/28.6.1102
103. Jump, D. B. (2002). Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr. Opin. Lipidol. 13, 155-164. doi: 10.1097/00041433-200204000-00007
104. Kachroo, A., Irizarry, M. C., and Schwarzschild, M. A. (2010). Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp. Neurol. 223, 657-661. doi: 10.1016/j.expneurol.2010.02.007
105. Kaikkonen, J., Nyyssonen, K., Tuomainen, T. P., Ristonmaa, U., and Salonen, J. T. (1999). Determinants of plasma coenzyme Q10 in humans. FEBS Lett. 443, 163-166. doi: 10.1016/S0014-5793(98)01712-8
106. Kamel, F. (2013). Epidemiology. Paths from pesticides to Parkinson's. Science 341, 722-723. doi: 10.1126/science.1243619
107. Kamel, F., Goldman, S. M., Umbach, D. M., Chen, H., Richardson, G., Barber, M. R., et al. (2013). Dietary fat intake, pesticide use, and Parkinson's disease. Parkinsonism Relat. Disord. 20, 82-87. doi: 10.1016/j.parkreldis.2013.09.023
108. Kandinov, B., Giladi, N., and Korczyn, A. D. (2009). Smoking and tea consumption delay onset of Parkinson's disease. Parkinsonism Relat. Disord. 15, 41-46. doi: 10.1016/j.parkreldis.2008.02.011
109. Kaur, H., Chauhan, S., and Sandhir, R. (2011). Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson's disease. Neurochem. Res. 36, 1435-1443. doi: 10.1007/s11064-011-0469-3
110. Khan, M. M., Ahmad, A., Ishrat, T., Khan, M. B., Hoda, M. N., Khuwaja, G., et al. (2010). Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res. 1328, 139-151. doi: 10.1016/j.brainres.2010.02.031
111. Kim, H. Y., Akbar, M., and Kim, K. Y. (2001). Inhibition of neuronal apoptosis by polyunsaturated fatty acids. J. Mol. Neurosci. 16, 223-227. discussion: 279-284. doi: 10.1385/JMN:16:2-3:223
112. Kim, J. S., Kim, J. M., O, J. J., and Jeon, B. S. (2010). Inhibition of inducible nitric oxide synthase expression and cell death by (-)-epigallocatechin-3-gallate, a green tea catechin, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Clin. Neurosci. 17, 1165-1168. doi: 10.1016/j.jocn.2010.01.042
113. Kim, K. Y., Stevens, M. V., Akter, M. H., Rusk, S. E., Huang, R. J., Cohen, A., et al. (2011). Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. J. Clin. Invest. 121, 3701-3712. doi: 10.1172/JCI44736
114. Kim, S., Lee, M. J., Hong, J., Li, C., Smith, T. J., Yang, G. Y., et al. (2000). Plasma and tissue levels of tea catechins in rats and mice during chronic consumption of green tea polyphenols. Nutr. Cancer 37, 41-48. doi: 10.1207/S15327914NC3701_5
115. Kish, S. J., Morito, C., and Hornykiewicz, O. (1985). Glutathione peroxidase activity in Parkinson's disease brain. Neurosci. Lett. 58, 343-346. doi: 10.1016/0304-3940(85)90078-3
116. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608. doi: 10.1038/33416
117. Kotagal, V., Albin, R. L., Muller, M. L., Koeppe, R. A., Frey, K. A., and Bohnen, N. I. (2013). Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat. Disord. 19, 522-526. doi: 10.1016/j.parkreldis.2013.01.016
118. Kyrozis, A., Ghika, A., Stathopoulos, P., Vassilopoulos, D., Trichopoulos, D., and Trichopoulou, A. (2013). Dietary and lifestyle variables in relation to incidence of Parkinson's disease in Greece. Eur. J. Epidemiol. 28, 67-77. doi: 10.1007/s10654-012-9760-0
119. Kyuhou, S. (2008). Preventive effects of genistein on motor dysfunction following 6-hydroxydopamine injection in ovariectomized rats. Neurosci. Lett. 448, 10-14. doi: 10.1016/j.neulet.2008.10.045
120. Lamperti, E. (1991). "Decreased concentration of low density lipoprotein cholesterol in patients with parkinson's disease," in Clinical Research, Vol. 39, eds R. Musanti, N. Rocca, G. Ghiselli, and E. Parat, 401A.
121. Lan, J., and Jiang, D. H. (1997). Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm. 104, 469-481. doi: 10.1007/BF01277665
122. Langie, S. A., Lara, J., and Mathers, J. C. (2012). Early determinants of the ageing trajectory. Best Pract. Res. Clin. Endocrinol. Metab. 26, 613-626. doi: 10.1016/j.beem.2012.03.004
123. Leaver, K. R., Allbutt, H. N., Creber, N. J., Kassiou, M., and Henderson, J. M. (2009). Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not neuroprotection. Brain Res. Bull. 80, 397-402. doi: 10.1016/j.brainresbull.2009.08.013
124. Levites, Y., Weinreb, O., Maor, G., Youdim, M. B., and Mandel, S. (2001). Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78, 1073-1082. doi: 10.1046/j.1471-4159.2001.00490.x
125. Lewitt, P. A. (1994). Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment. J. Neural Transm. Suppl. 43, 171-181.
126. Li, R., Huang, Y. G., Fang, D., and Le, W. D. (2004). (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. J. Neurosci. Res. 78, 723-731. doi: 10.1002/jnr.20315
127. Liu, L. X., Chen, W. F., Xie, J. X., and Wong, M. S. (2008). Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neurosci. Res. 60, 156-161. doi: 10.1016/j.neures.2007.10.005
128. Liu, R., Guo, X., Park, Y., Wang, J., Huang, X., Hollenbeck, A., et al. (2013). Alcohol consumption, types of alcohol, and Parkinson's disease. PLoS ONE 8:e66452. doi: 10.1371/journal.pone.0066452
129. Liu, R. H. (2003). Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am. J. Clin. Nutr. 78, 517S-520S.
130. Logroscino, G., Gao, X., Chen, H., Wing, A., and Ascherio, A. (2008). Dietary iron intake and risk of Parkinson's disease. Am. J. Epidemiol. 168, 1381-1388. doi: 10.1093/aje/kwn273
131. Logroscino, G., Marder, K., Cote, L., Tang, M. X., Shea, S., and Mayeux, R. (1996). Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann. Neurol. 39, 89-94. doi: 10.1002/ana.410390113
132. Logroscino, G., Marder, K., Graziano, J., Freyer, G., Slavkovich, V., Lojacono, N., et al. (1998). Dietary iron, animal fats, and risk of Parkinson's disease. Mov. Disord. 13(Suppl. 1), 13-16.
133. Lu, K. T., Ko, M. C., Chen, B. Y., Huang, J. C., Hsieh, C. W., Lee, M. C., et al. (2008). Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J. Agric. Food Chem. 56, 6910-6913. doi: 10.1021/jf8007212
134. Luchtman, D. W., Meng, Q., and Song, C. (2012). Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. Behav. Brain Res. 226, 386-396. doi: 10.1016/j.bbr.2011.09.033
135. Luchtman, D. W., Meng, Q., Wang, X., Shao, D., and Song, C. (2013). omega-3 fatty acid eicosapentaenoic acid attenuates MPP+-induced neurodegeneration in fully differentiated human SH-SY5Y and primary mesencephalic cells. J. Neurochem. 124, 855-868. doi: 10.1111/jnc.12068
136. Massaro, M., Habib, A., Lubrano, L., Del Turco, S., Lazzerini, G., Bourcier, T., et al. (2006). The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. Proc. Natl. Acad. Sci. U.S.A. 103, 15184-15189. doi: 10.1073/pnas.0510086103
137. Massey, V. (2000). The chemical and biological versatility of riboflavin. Biochem. Soc. Trans. 28, 283-296. doi: 10.1042/0300-5127:0280283
138. Mattson, M. P. (2014). Interventions that improve body and brain bioenergetics for Parkinson's disease risk reduction and therapy. J. Parkinsons Dis. 4, 1-13. doi: 10.3233/JPD-130335
139. Meng, Q., Luchtman, D. W., El Bahh, B., Zidichouski, J. A., Yang, J., and Song, C. (2010). Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices. Eur. J. Pharmacol. 649, 127-134. doi: 10.1016/j.ejphar.2010.09.046
140. Micha, R., Wallace, S. K., and Mozaffarian, D. (2010). Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation 121, 2271-2283. doi: 10.1161/CIRCULATIONAHA.109.924977
141. Miyake, Y., Fukushima, W., Tanaka, K., Sasaki, S., Kiyohara, C., Tsuboi, Y., et al. (2011a). Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case-control study in Japan. Eur. J. Neurol. 18, 106-113. doi: 10.1111/j.1468-1331.2010.03088.x
142. Miyake, Y., Tanaka, K., Fukushima, W., Sasaki, S., Kiyohara, C., Tsuboi, Y., et al. (2011b). Dietary intake of metals and risk of Parkinson's disease: a case-control study in Japan. J. Neurol. Sci. 306, 98-102. doi: 10.1016/j.jns.2011.03.035
143. Miyake, Y., Tanaka, K., Fukushima, W., Sasaki, S., Kiyohara, C., Tsuboi, Y., et al. (2011c). Lack of association of dairy food, calcium, and vitamin D intake with the risk of Parkinson's disease: a case-control study in Japan. Parkinsonism Relat. Disord. 17, 112-116. doi: 10.1016/j.parkreldis.2010.11.018
144. Morelli, M., Carta, A. R., Kachroo, A., and Schwarzschild, M. A. (2010). Pathophysiological roles for purines: adenosine, caffeine and urate. Prog. Brain Res. 183, 183-208. doi: 10.1016/S0079-6123(10)83010-9
145. Moreno, J. J., and Mitjavila, M. T. (2003). The degree of unsaturation of dietary fatty acids and the development of atherosclerosis (review). J. Nutr. Biochem. 14, 182-195. doi: 10.1016/S0955-2863(02)00294-2
146. Morris, J. K., Bomhoff, G. L., Stanford, J. A., and Geiger, P. C. (2010). Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299, R1082-R1090. doi: 10.1152/ajpregu.00449.2010
147. Morroni, F., Tarozzi, A., Sita, G., Bolondi, C., Zolezzi Moraga, J. M., Cantelli-Forti, G., et al. (2013). Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease. Neurotoxicology 36, 63-71. doi: 10.1016/j.neuro.2013.03.004
148. Murakami, K., Miyake, Y., Sasaki, S., Tanaka, K., Fukushima, W., Kiyohara, C., et al. (2010a). Dietary glycemic index is inversely associated with the risk of Parkinson's disease: a case-control study in Japan. Nutrition 26, 515-521. doi: 10.1016/j.nut.2009.05.021
149. Murakami, K., Miyake, Y., Sasaki, S., Tanaka, K., Fukushima, W., Kiyohara, C., et al. (2010b). Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson's disease: a case-control study in Japan. Br. J. Nutr. 104, 757-764. doi: 10.1017/S0007114510001005
150. Musanti, R., Parati, E., Lamperti, E., and Ghiselli, G. (1993). Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease. Biochem. Med. Metab. Biol. 49, 133-142. doi: 10.1006/bmmb.1993.1016
151. Nakaso, K., Ito, S., and Nakashima, K. (2008). Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells. Neurosci. Lett. 432, 146-150. doi: 10.1016/j.neulet.2007.12.034
152. Nie, G., Cao, Y., and Zhao, B. (2002). Protective effects of green tea polyphenols and their major component, (-)-epigallocatechin-3-gallate (EGCG), on 6-hydroxydopamine-induced apoptosis in PC12 cells. Redox Rep. 7, 171-177. doi: 10.1179/135100002125000424
153. Noyce, A. J., Bestwick, J. P., Silveira-Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., et al. (2012). Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurol. 72, 893-901. doi: 10.1002/ana.23687
154. Oba, S., Nanri, A., Kurotani, K., Goto, A., Kato, M., Mizoue, T., et al. (2013). Dietary glycemic index, glycemic load and incidence of type 2 diabetes in Japanese men and women: the Japan public health center-based prospective study. Nutr. J. 12, 165. doi: 10.1186/1475-2891-12-165
155. Offen, D., Ziv, I., Sternin, H., Melamed, E., and Hochman, A. (1996). Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp. Neurol. 141, 32-39. doi: 10.1006/exnr.1996.0136
156. Okawara, M., Katsuki, H., Kurimoto, E., Shibata, H., Kume, T., and Akaike, A. (2007). Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem. Pharmacol. 73, 550-560. doi: 10.1016/j.bcp.2006.11.003
157. Okubo, H., Miyake, Y., Sasaki, S., Murakami, K., Tanaka, K., Fukushima, W., et al. (2012). Dietary patterns and risk of Parkinson's disease: a case-control study in Japan. Eur. J. Neurol. 19, 681-688. doi: 10.1111/j.1468-1331.2011.03600.x
158. O'Reilly, E. J., Gao, X., Weisskopf, M. G., Chen, H., Schwarzschild, M. A., Spiegelman, D., et al. (2010). Plasma urate and Parkinson's disease in women. Am. J. Epidemiol. 172, 666-670. doi: 10.1093/aje/kwq195
159. Osakada, F., Hashino, A., Kume, T., Katsuki, H., Kaneko, S., and Akaike, A. (2004). Alpha-tocotrienol provides the most potent neuroprotection among vitamin E analogs on cultured striatal neurons. Neuropharmacology 47, 904-915. doi: 10.1016/j.neuropharm.2004.06.029
160. Ozsoy, O., Seval-Celik, Y., Hacioglu, G., Yargicoglu, P., Demir, R., Agar, A., et al. (2011). The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson's disease. Neurochem. Int. 59, 664-670. doi: 10.1016/j.neuint.2011.06.012
161. Paiva, S. A., and Russell, R. M. (1999). Beta-carotene and other carotenoids as antioxidants. J. Am. Coll. Nutr. 18, 426-433. doi: 10.1080/07315724.1999.10718880
162. Palacios, N., Gao, X., McCullough, M. L., Jacobs, E. J., Patel, A. V., Mayo, T., et al. (2011). Obesity, diabetes, and risk of Parkinson's disease. Mov. Disord. 26, 2253-2259. doi: 10.1002/mds.23855
163. Palacios, N., Gao, X., McCullough, M. L., Schwarzschild, M. A., Shah, R., Gapstur, S., et al. (2012a). Caffeine and risk of Parkinson's disease in a large cohort of men and women. Mov. Disord. 27, 1276-1282. doi: 10.1002/mds.25076
164. Palacios, N., Gao, X., O'Reilly, E., Schwarzschild, M., McCullough, M. L., Mayo, T., et al. (2012b). Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women. Mov. Disord. 27, 980-987. doi: 10.1002/mds.25050
165. Pallas, M., Casadesus, G., Smith, M. A., Coto-Montes, A., Pelegri, C., Vilaplana, J., et al. (2009). Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection. Curr. Neurovasc. Res. 6, 70-81. doi: 10.2174/156720209787466019
166. Pan, T., Fei, J., Zhou, X., Jankovic, J., and Le, W. (2003a). Effects of green tea polyphenols on dopamine uptake and on MPP+-induced dopamine neuron injury. Life Sci. 72, 1073-1083. doi: 10.1016/S0024-3205(02)02347-0
167. Pan, T., Jankovic, J., and Le, W. (2003b). Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging 20, 711-721. doi: 10.2165/00002512-200320100-00001
168. Pare, S., Barr, S. I., and Ross, S. E. (1992). Effect of daytime protein restriction on nutrient intakes of free-living Parkinson's disease patients. Am. J. Clin. Nutr. 55, 701-707.
169. Park, L. K., Friso, S., and Choi, S. W. (2012). Nutritional influences on epigenetics and age-related disease. Proc. Nutr. Soc. 71, 75-83. doi: 10.1017/S0029665111003302
170. Park, M., Ross, G. W., Petrovitch, H., White, L. R., Masaki, K. H., Nelson, J. S., et al. (2005). Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology 64, 1047-1051. doi: 10.1212/01.WNL.0000154532.98495.BF
171. Peers, R. (1997). Fatty diet, mitochondria and Parkinson's disease. N. Z. Med. J. 110, 132.
172. Perry, T. L., Yong, V. W., Clavier, R. M., Jones, K., Wright, J. M., Foulks, J. G., et al. (1985). Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 60, 109-114. doi: 10.1016/0304-3940(85)90229-0
173. Perry, T. L., Yong, V. W., Hansen, S., Jones, K., Bergeron, C., Foulks, J. G., et al. (1987). Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurol. Sci. 81, 321-331. doi: 10.1016/0022-510X(87)90106-7
174. Pincus, J. H., and Barry, K. M. (1987). Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch. Neurol. 44, 1006-1009. doi: 10.1001/archneur.1987.00520220012007
175. Ponsen, M. M., Stoffers, D., Booij, J., Van Eck-Smit, B. L., Wolters, E., and Berendse, H. W. (2004). Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 56, 173-181. doi: 10.1002/ana.20160
176. Popoli, P., Minghetti, L., Tebano, M. T., Pintor, A., Domenici, M. R., and Massotti, M. (2004). Adenosine A2A receptor antagonism and neuroprotection: mechanisms, lights, and shadows. Crit. Rev. Neurobiol. 16, 99-106. doi: 10.1615/CritRevNeurobiol.v16.i12.110
177. Powers, K. M., Smith-Weller, T., Franklin, G. M., Longstreth, W. T. Jr., Swanson, P. D., and Checkoway, H. (2003). Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 60, 1761-1766. doi: 10.1212/01.WNL.0000068021.13945.7F
178. Prakash, K. M., and Tan, E. K. (2011). Clinical evidence linking coffee and tea intake with Parkinson's disease. Basal Ganglia 1, 127-130. doi: 10.1016/j.baga.2011.07.001
179. Prediger, R. D. (2010). Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. J. Alzheimers Dis 20(Suppl. 1), S205-S220. doi: 10.3233/JAD-2010-091459
180. Qian, Y., Guan, T., Huang, M., Cao, L., Li, Y., Cheng, H., et al. (2012). Neuroprotection by the soy isoflavone, genistein, via inhibition of mitochondria-dependent apoptosis pathways and reactive oxygen induced-NF-kappaB activation in a cerebral ischemia mouse model. Neurochem. Int. 60, 759-767. doi: 10.1016/j.neuint.2012.03.011
181. Qureshi, I. A., and Mehler, M. F. (2013). Epigenetic mechanisms governing the process of neurodegeneration. Mol. Aspects Med. 34, 875-882. doi: 10.1016/j.mam.2012.06.011
182. Ragonese, P., Salemi, G., Morgante, L., Aridon, P., Epifanio, A., Buffa, D., et al. (2003). A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson's disease. Neuroepidemiology 22, 297-304. doi: 10.1159/000071193
183. Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G. P., Jellinger, K., et al. (1989). Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520. doi: 10.1111/j.1471-4159.1989.tb09150.x
184. Robinson, L. E., and Mazurak, V. C. (2013). N-3 polyunsaturated fatty acids: relationship to inflammation in healthy adults and adults exhibiting features of metabolic syndrome. Lipids 48, 319-332. doi: 10.1007/s11745-013-3774-6
185. Roghani, M., and Behzadi, G. (2001). Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res. 892, 211-217. doi: 10.1016/S0006-8993(00)03296-0
186. Rohrmann, S., Overvad, K., Bueno-De-Mesquita, H. B., Jakobsen, M. U., Egeberg, R., Tjonneland, A., et al. (2013). Meat consumption and mortality-results from the European Prospective Investigation into Cancer and Nutrition. BMC Med. 11:63. doi: 10.1186/1741-7015-11-63
187. Ryu, E. J., Harding, H. P., Angelastro, J. M., Vitolo, O. V., Ron, D., and Greene, L. A. (2002). Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J. Neurosci. 22, 10690-10698.
188. Saaksjarvi, K., Knekt, P., Lundqvist, A., Mannisto, S., Heliovaara, M., Rissanen, H., et al. (2013). A cohort study on diet and the risk of Parkinson's disease: the role of food groups and diet quality. Br. J. Nutr. 109, 329-337. doi: 10.1017/S0007114512000955
189. Sakamoto, T., Cansev, M., and Wurtman, R. J. (2007). Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res. 1182, 50-59. doi: 10.1016/j.brainres.2007.08.089
190. Salem, M. L., Kishihara, K., Abe, K., Matsuzaki, G., and Nomoto, K. (2000). N-3 polyunsaturated fatty acids accentuate B16 melanoma growth and metastasis through suppression of tumoricidal function of T cells and macrophages. Anticancer Res. 20, 3195-3203.
191. Salmeron, J., Ascherio, A., Rimm, E. B., Colditz, G. A., Spiegelman, D., Jenkins, D. J., et al. (1997a). Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care 20, 545-550. doi: 10.2337/diacare.20.4.545
192. Salmeron, J., Manson, J. E., Stampfer, M. J., Colditz, G. A., Wing, A. L., and Willett, W. C. (1997b). Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 277, 472-477. doi: 10.1001/jama.1997.03540300040031
193. Samadi, P., Gregoire, L., Rouillard, C., Bedard, P. J., Di Paolo, T., and Levesque, D. (2006). Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann. Neurol. 59, 282-288. doi: 10.1002/ana.20738
194. Santiago, J. A., and Potashkin, J. A. (2013a). Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes. PLoS ONE 8:e83940. doi: 10.1371/journal.pone.0083940
195. Santiago, J. A., and Potashkin, J. A. (2013b). Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol. Med. 19, 176-186. doi: 10.1016/j.molmed.2013.01.002
196. Santos, L. F., Freitas, R. L., Xavier, S. M., Saldanha, G. B., and Freitas, R. M. (2008). Neuroprotective actions of vitamin C related to decreased lipid peroxidation and increased catalase activity in adult rats after pilocarpine-induced seizures. Pharmacol. Biochem. Behav. 89, 1-5. doi: 10.1016/j.pbb.2007.10.007
197. Sarkaki, A., Badavi, M., Aligholi, H., and Moghaddam, A. Z. (2009). Preventive effects of soy meal (+/- isoflavone) on spatial cognitive deficiency and body weight in an ovariectomized animal model of Parkinson's disease. Pak. J. Biol. Sci. 12, 1338-1345. doi: 10.3923/pjbs.2009.1338.1345
198. Sato, Y., Kikuyama, M., and Oizumi, K. (1997). High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 49, 1273-1278. doi: 10.1212/WNL.49.5.1273
199. Scheider, W. L., Hershey, L. A., Vena, J. E., Holmlund, T., Marshall, J. R., and Freudenheim (1997). Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mov. Disord. 12, 190-196. doi: 10.1002/mds.870120209
200. Schernhammer, E., Hansen, J., Rugbjerg, K., Wermuth, L., and Ritz, B. (2011). Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 34, 1102-1108. doi: 10.2337/dc10-1333
201. Schipper, H. M. (2000). Heme oxygenase-1: role in brain aging and neurodegeneration. Exp. Gerontol. 35, 821-830. doi: 10.1016/S0531-5565(00)00148-0
202. Schlesinger, I., and Schlesinger, N. (2008). Uric acid in Parkinson's disease. Mov. Disord. 23, 1653-1657. doi: 10.1002/mds.22139
203. Searles Nielsen, S., Franklin, G. M., Longstreth, W. T., Swanson, P. D., and Checkoway, H. (2013). Nicotine from edible Solanaceae and risk of Parkinson disease. Ann. Neurol. 74, 472-477. doi: 10.1002/ana.23884
204. Serhan, C. N., and Petasis, N. A. (2011). Resolvins and protectins in inflammation resolution. Chem. Rev. 111, 5922-5943. doi: 10.1021/cr100396c
205. Shaltiel-Karyo, R., Frenkel-Pinter, M., Rockenstein, E., Patrick, C., Levy-Sakin, M., Schiller, A., et al. (2013). A blood-brain barrier (BBB) disrupter is also a potent alpha-synuclein (alpha-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD). J. Biol. Chem. 288, 17579-17588. doi: 10.1074/jbc. M112.434787
206. Shen, C., Guo, Y., Luo, W., Lin, C., and Ding, M. (2013). Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can. J. Neurol. Sci. 40, 73-79.
207. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., et al. (2000). Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302-305. doi: 10.1038/77060
208. Shults, C. W., Flint Beal, M., Song, D., and Fontaine, D. (2004). Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp. Neurol. 188, 491-494. doi: 10.1016/j.expneurol.2004.05.003
209. Simon, K. C., Chen, H., Schwarzschild, M., and Ascherio, A. (2007). Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69, 1688-1695. doi: 10.1212/01.wnl.0000271883.45010.8a
210. Simopoulos, A. P. (1999). Essential fatty acids in health and chronic disease. Am. J. Clin. Nutr. 70, 560S-569S.
211. Smith, M. P., Fletcher-Turner, A., Yurek, D. M., and Cass, W. A. (2006). Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem. Res. 31, 533-539. doi: 10.1007/s11064-006-9048-4
212. Song, C., Zhang, X. Y., and Manku, M. (2009). Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. J. Neurosci. 29, 14-22. doi: 10.1523/JNEUROSCI.3569-08.2009
213. Sonsalla, P. K., Wong, L. Y., Harris, S. L., Richardson, J. R., Khobahy, I., Li, W., et al. (2012). Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease. Exp. Neurol. 234, 482-487. doi: 10.1016/j.expneurol.2012.01.022
214. Storch, A., Kaftan, A., Burkhardt, K., and Schwarz, J. (2000). 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. J. Neural Transm. 107, 281-293. doi: 10.1007/s007020050023
215. Sun, Y., Chang, Y. H., Chen, H. F., Su, Y. H., Su, H. F., and Li, C. Y. (2012). Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care 35, 1047-1049. doi: 10.2337/dc11-1511
216. Suzuki, M., Yoshioka, M., Hashimoto, M., Murakami, M., Noya, M., Takahashi, D., et al. (2013). Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am. J. Clin. Nutr. 97, 1004-1013. doi: 10.3945/ajcn.112.051664
217. Taepavarapruk, P., and Song, C. (2010). Reductions of acetylcholine release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1beta administrations: effects of omega-3 fatty acid EPA treatment. J. Neurochem. 112, 1054-1064. doi: 10.1111/j.1471-4159.2009.06524.x
218. Tan, L. C., Koh, W. P., Yuan, J. M., Wang, R., Au, W. L., Tan, J. H., et al. (2008). Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. Am. J. Epidemiol. 167, 553-560. doi: 10.1093/aje/kwm338
219. Tanaka, K., Miyake, Y., Fukushima, W., Sasaki, S., Kiyohara, C., Tsuboi, Y., et al. (2011). Intake of Japanese and Chinese teas reduces risk of Parkinson's disease. Parkinsonism Relat. Disord. 17, 446-450. doi: 10.1016/j.parkreldis.2011.02.016
220. Tapias, V., Cannon, J. R., and Greenamyre, J. T. (2013). Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease. Neurobiol. Aging. 35, 1162-1176. doi: 10.1016/j.neurobiolaging.2013.10.077
221. Tarozzi, A., Angeloni, C., Malaguti, M., Morroni, F., Hrelia, S., and Hrelia, P. (2013). Sulforaphane as a potential protective phytochemical against neurodegenerative diseases. Oxid. Med. Cell. Longev. 2013:415078. doi: 10.1155/2013/415078
222. Tarozzi, A., Morroni, F., Bolondi, C., Sita, G., Hrelia, P., Djemil, A., et al. (2012). Neuroprotective effects of erucin against 6-hydroxydopamine-induced oxidative damage in a dopaminergic-like neuroblastoma cell line. Int. J. Mol. Sci. 13, 10899-10910. doi: 10.3390/ijms130910899
223. Uttara, B., Singh, A. V., Zamboni, P., and Mahajan, R. T. (2009). Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 7, 65-74. doi: 10.2174/157015909787602823
224. Vanitallie, T. B., Nonas, C., Di Rocco, A., Boyar, K., Hyams, K., and Heymsfield, S. B. (2005). Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology 64, 728-730. doi: 10.1212/01.WNL.0000152046.11390.45
225. Wang, J. Y., Sekine, S., and Saito, M. (2003). Effect of docosahexaenoic acid and ascorbate on peroxidation of retinal membranes of ODS rats. Free Radic. Res. 37, 419-424. doi: 10.1080/1071576031000070084
226. Wang, J. Y., Wu, J. N., Cherng, T. L., Hoffer, B. J., Chen, H. H., Borlongan, C. V., et al. (2001). Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 904, 67-75. doi: 10.1016/S0006-8993(01)02450-7
227. Wang, L., Zhai, Y. Q., Xu, L. L., Qiao, C., Sun, X. L., Ding, J. H., et al. (2014). Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. Exp. Neurol. 251, 22-29. doi: 10.1016/j.expneurol.2013.11.001
228. Wang, X., Chen, S., Ma, G., Ye, M., and Lu, G. (2005). Genistein protects dopaminergic neurons by inhibiting microglial activation. Neuroreport 16, 267-270. doi: 10.1097/00001756-200502280-00013
229. Warner, T. T., and Schapira, A. H. (2003). Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol. 53(Suppl. 3), S16-S23. discussion: S23-S15.
230. Weinreb, O., Amit, T., Mandel, S., and Youdim, M. B. (2009). Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr. 4, 283-296. doi: 10.1007/s12263-009-0143-4
231. Weinreb, O., Mandel, S., Amit, T., and Youdim, M. B. (2004). Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J. Nutr. Biochem. 15, 506-516. doi: 10.1016/j.jnutbio.2004.05.002
232. Weisskopf, M. G., O'Reilly, E., Chen, H., Schwarzschild, M. A., and Ascherio, A. (2007). Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 166, 561-567. doi: 10.1093/aje/kwm127
233. Wu, A., Ying, Z., and Gomez-Pinilla, F. (2004). Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J. Neurotrauma 21, 1457-1467. doi: 10.1089/neu.2004.21.1457
234. Wurtman, R. J., Ulus, I. H., Cansev, M., Watkins, C. J., Wang, L., and Marzloff, G. (2006). Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res. 1088, 83-92. doi: 10.1016/j.brainres.2006.03.019
235. Wurtman, R. J., Wurtman, J. J., Regan, M. M., McDermott, J. M., Tsay, R. H., and Breu, J. J. (2003). Effects of normal meals rich in carbohydrates or proteins on plasma tryptophan and tyrosine ratios. Am. J. Clin. Nutr. 77, 128-132.
236. Xiao, D., Cassin, J. J., Healy, B., Burdett, T. C., Chen, J. F., Fredholm, B. B., et al. (2011). Deletion of adenosine A(1) or A((2)A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Res. 1367, 310-318. doi: 10.1016/j.brainres.2010.08.099
237. Xu, K., Xu, Y., Brown-Jermyn, D., Chen, J. F., Ascherio, A., Dluzen, D. E., et al. (2006). Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 26, 535-541. doi: 10.1523/JNEUROSCI.3008-05.2006
238. Xu, K., Xu, Y. H., Chen, J. F., and Schwarzschild, M. A. (2002). Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci. Lett. 322, 13-16. doi: 10.1016/S0304-3940(02)00069-1
239. Xu, K., Xu, Y. H., Chen, J. F., and Schwarzschild, M. A. (2010). Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience 167, 475-481. doi: 10.1016/j.neuroscience.2010.02.020
240. Xu, Q., Park, Y., Huang, X., Hollenbeck, A., Blair, A., Schatzkin, A., et al. (2011). Diabetes and risk of Parkinson's disease. Diabetes Care 34, 910-915. doi: 10.2337/dc10-1922
241. Yadav, S., Gupta, S. P., Srivastava, G., Srivastava, P. K., and Singh, M. P. (2012). Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. Neurochem. Res. 37, 875-884. doi: 10.1007/s11064-011-0682-0
242. Ye, Q., Ye, L., Xu, X., Huang, B., Zhang, X., Zhu, Y., et al. (2012). Epigallocatechin-3-gallate suppresses 1-methyl-4-phenyl-pyridine-induced oxidative stress in PC12 cells via the SIRT1/PGC-1alpha signaling pathway. BMC Complement. Altern. Med. 12:82. doi: 10.1186/1472-6882-12-82
243. Yong, V. W., Perry, T. L., and Krisman, A. A. (1986). Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. Neurosci. Lett. 63, 56-60. doi: 10.1016/0304-3940(86)90012-1
244. Youdim, K. A., Martin, A., and Joseph, J. A. (2000). Essential fatty acids and the brain: possible health implications. Int. J. Dev. Neurosci. 18, 383-399. doi: 10.1016/S0736-5748(00)00013-7
245. Zhang, F., Shi, J. S., Zhou, H., Wilson, B., Hong, J. S., and Gao, H. M. (2010). Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol. Pharmacol. 78, 466-477. doi: 10.1124/mol.110.064535
246. Zhang, S. M., Hernan, M. A., Chen, H., Spiegelman, D., Willett, W. C., and Ascherio, A. (2002). Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59, 1161-1169. doi: 10.1212/01.WNL.0000028688.75881.12
247. Zhang, W., Li, R., Li, J., Wang, W., Tie, R., Tian, F., et al. (2013). Alpha-linolenic acid exerts an endothelial protective effect against high glucose injury via PI3K/Akt pathway. PLoS ONE 8:e68489. doi: 10.1371/journal.pone.0068489
248. Zhao, B. (2009). Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease. Neurochem. Res. 34, 630-638. doi: 10.1007/s11064-008-9900-9
249. Zhu, B. T., Shim, J. Y., Nagai, M., and Bai, H. W. (2008). Molecular modelling study of the mechanism of high-potency inhibition of human catechol-O-methyltransferase by (-)-epigallocatechin-3-O-gallate. Xenobiotica 38, 130-146. doi: 10.1080/00498250701744641